What Is Humanin? Dosage, Half-Life & How to Track It

What Humanin is and how it works

Humanin was discovered inside the 16S ribosomal RNA region of mitochondrial DNA — a part of the genome not thought to code for a functional peptide until Humanin’s protective effect on neurons turned up in Alzheimer’s-related research in the early 2000s. It is now the best-studied member of a small family of mitochondrial-derived peptides (MDPs), signaling molecules that originate from mitochondria rather than the nuclear genome most peptides come from.

Mechanistically, Humanin is described as cytoprotective — it appears to interfere with apoptotic (programmed cell death) signaling in stressed cells, and has been studied for protective effects in models of Alzheimer’s disease, cardiovascular injury, and metabolic stress. A related, more consistent finding is that circulating Humanin levels decline with age in both animal models and human observational studies, part of why it is discussed alongside other proposed longevity biomarkers.

The evidence base here is genuinely early. Almost all of the mechanistic and efficacy data comes from cell culture and animal studies; a more potent lab analog, HNG (S14G-Humanin), is what most of that animal research actually uses, because native Humanin’s very short half-life makes it a poor experimental tool on its own. Human dosing and safety data for either form is essentially absent from the published literature.

Typical dosing & reconstitution

Where Humanin is used in a self-directed research context, it ships as a lyophilized powder reconstituted with bacteriostatic water, in line with other short peptides. Because there is no validated human dosing study to draw from, described protocols are extrapolated from research-community reporting rather than clinical data.

At 1.67 mg/mL, a 100 mcg dose is 6 units and a 200 mcg dose is 12 units on a standard U-100 syringe. These figures describe reconstitution math for a research-vial format, not a clinically validated human dose — the calculator handles the arithmetic regardless of how established the underlying protocol is.

Half-life & what it means for frequency

Native Humanin is degraded quickly in circulation — on the order of minutes — which is exactly why researchers developed HNG, a modified analog with a single amino-acid substitution that resists degradation and extends activity, for use in most animal studies. Community research protocols using native Humanin default to once-daily dosing on the assumption that frequent dosing is needed to maintain any exposure at all.

This is a case where the pharmacokinetic uncertainty is itself the headline: without human trial data, there is no way to say with confidence what dosing interval would actually sustain a meaningful effect in a person, native peptide or analog.

What to track & common side effects

There is no established human side-effect profile for Humanin — it has not been through the kind of trials that would generate one. That absence of data is the most important fact here, not a reason to assume it is risk-free.

If tracking Humanin, the honest framing is the same as for the other thin-evidence compounds in this library: log dose, timing, and any change you notice, understanding you are contributing to your own n=1 record in the near-total absence of human research to compare it against.

Frequently asked questions